Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
4.610
+0.260 (5.98%)
At close: Sep 4, 2026, 4:00 PM EDT
4.690
+0.080 (1.74%)
After-hours: Sep 4, 2026, 7:58 PM EDT
Galectin Therapeutics Market Cap
Galectin Therapeutics has a market cap or net worth of $464.92 million as of September 4, 2026. Its market cap has increased by 61.65% in one year.
Market Cap
464.92M
Enterprise Value
595.60M
1-Year Change
61.65%
Ranking
Category
Stock Price
$4.61
ChartMarket Cap Chart
Since September 10, 2003, Galectin Therapeutics's market cap has increased from $106.80M to $464.92M, an increase of 335.32%. That is a compound annual growth rate of 6.60%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 4, 2026 | 464.92M | 73.35% |
| Dec 31, 2025 | 268.20M | 231.11% |
| Dec 31, 2024 | 81.00M | -21.13% |
| Dec 29, 2023 | 102.70M | 52.83% |
| Dec 30, 2022 | 67.20M | -45.28% |
| Dec 31, 2021 | 122.80M | -3.99% |
| Dec 31, 2020 | 127.90M | -21.39% |
| Dec 31, 2019 | 162.70M | 15.31% |
| Dec 31, 2018 | 141.10M | 18.57% |
| Dec 29, 2017 | 119.00M | 313.19% |
| Dec 30, 2016 | 28.80M | -26.53% |
| Dec 31, 2015 | 39.20M | -48.96% |
| Dec 31, 2014 | 76.80M | -48.11% |
| Dec 31, 2013 | 148.00M | 352.60% |
| Dec 31, 2012 | 32.70M | -55.81% |
| Dec 30, 2011 | 74.00M | 32.14% |
| Dec 31, 2010 | 56.00M | 288.89% |
| Dec 31, 2009 | 14.40M | 234.88% |
| Dec 31, 2008 | 4.30M | -84.81% |
| Dec 31, 2007 | 28.30M | 111.19% |
| Dec 29, 2006 | 13.40M | -83.91% |
| Dec 30, 2005 | 83.30M | 21.96% |
| Dec 31, 2004 | 68.30M | -23.94% |
| Dec 31, 2003 | 89.80M | -15.92% |
| Sep 10, 2003 | 106.80M | - |
View and export this data all the way back to 2003. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| C4 Therapeutics | 460.11M |
| Inhibikase Therapeutics | 458.83M |
| Ocugen | 457.80M |
| Vogenx | 447.45M |
| Arcturus Therapeutics Holdings | 442.26M |
| Fennec Pharmaceuticals | 440.09M |
| Evommune | 435.51M |
| Benitec Biopharma | 427.37M |